DprE1-IN-2_DataSheet_MedChemExpress
D-Dimer资料
D-二聚体（D-Dimer）测定（双向测流免疫法）1 实验原理检验时样品中的待检物首先与化学偶合物垫上的特异性抗体1偶合物发生免疫反应形成免疫复合物，其后免疫复合物随着血样在硝基纤维素膜上层析流动，当免疫复合物层析至硝基纤维素膜上的检测区时，与已预先包被在硝基纤维素膜上的特异性抗体2发生反应从而被固定在硝基纤维素膜的检测区上。
因此待检物越多，测试带上的复合物越多，条带上的光密度值就越高。
反应结束后经过SSJ-2多功能免疫检测仪的分析处理，反映样本中待检物的浓度。
同时，在检测过程中，对照偶合物也会随缓冲液在硝基纤维素膜上层析，当层析至硝基纤维素膜的对照区（内控带1和内控带2）时，对照偶合物会与预先包被在硝基纤维素膜上的特异性抗体发生反应从而被固定在对照区上。
当样品中不含待检物时，则只在对照区（内控带1和内控带2）显示两条对照带。
任何情况下若无对照带显色或显色强度不够，则质控失控，需查明原因重新检测。
当反应结束后，SSJ-2多功能免疫检测仪将对检测条带的光密度进行分析，并将所分析得到的结果进行运算，从而得到相对光密度值（RI）。
然后检测仪根据已预先设置在检测仪内的标准曲线对检测物的浓度进行计算并显示结果。
2 标本采集详见《采样手册》。
3 标本存放3.1 本试剂适用于采用EDTA.K2或肝素抗凝的血清或血浆。
3.2 样本采集完后，请立即使用。
不应将样本在室温条件下长时间放置。
使用血清或血浆样本检测时，应尽快分离出血清或血浆，避免溶血，已严重溶血的样本请停止使用。
3.3 血清或血浆样本在2～8℃条件下可以保存三天，若长期保存应放置在—20℃以下保存，避免反复冻融。
3.4 所有的样本检测前必须恢复至室温才可使用。
4 标本运输执行《标本运送制度》。
5 标本拒收的标准执行《不合格标本退回记录单》。
6 实验材料6.1 瑞莱生物工程（深圳）有限公司D-二聚体（双向测流免疫法）检测试剂盒。
6.1.1 试剂组成成分D-二聚体检测试剂20人份（铝箔袋包装）缓冲液—A（一般化学试剂）1瓶（3.5mL）D-二聚体试剂说明书1份6.1.2 储存条件及有效期室温（15～30℃）、干燥、避光处保存，有效期18个月（生产日期至失效日期）。
QPCR及QRT-PCR系列产品
Invitrogen的ICFC系列产品促销1．QPCR及QRT-PCR系列产品Invitrogen公司专门为中国客户提供的定量PCR试剂盒，结合了 UDG 防止残余污染技术和SYBR® Green I 荧光染料（存在于SYBR® Green I荧光定量PCR试剂盒中），在美国接受了严格的质量监控，可提供极高灵敏度的目的序列定量检测，线性剂量低，反应浓度范围很大。
qPCR Supermix-- 即用型反应剂，专为高特异性、实时定量DNA扩增设计UDG-- 防止携带污染物，减少克隆片段假阳性结果ROX参考染料-- 适用ABI仪器的校正染料产品信息活动时间：即日起至2009年4月30日2．Gibco南美胎牛血清即日起凡优惠价¥1780购买Gibco胎牛血清500ml（目录号:C2027050）即可获赠送价值¥250现金抵用券。
您可以凭现金抵用券在英韦创津公司购买任何商品，此券有效期至2009年5月31日。
产品信息活动时间：即日起至2009年4月30日独特的采集方式：GIBCO采用无菌心脏穿刺的方式采血原装直送，避免污染：原产地采集、加工、检测、包装。
完善的质控：采集、处理、检测、运输等环节都有文件和证书。
3．Invitrogen TA Cloning克隆产品专门用于克隆Taq聚合酶扩增的PCR产物。
采用pCR载体，能产生80%以上的重组产物，90%以上重组产物都包含插入片段。
产品信息活动时间：即日起至2009年5月31日附：pCR载体优点及图谱：3’-T突出端可直接连接Taq扩增的PCR产物可选择T7或T7和Sp6启动子进行体外RNA转录和测序侧向EcoRⅠ位点的通用多接头位点方便了插入片段的切离可以选择卡那霉素或氨苄青霉素进行筛选非常简便的蓝/白克隆筛选具有M13正向和反向引物位点，方便测序4．GIBCO液体培养基系列产品创立近50年的历史，品质优秀，产品种类丰富；为了中国用户利益，特建立国内生产线；所有产品，从原材料到生产全部按照GIBCO质量标准进行，每批均送抵美国公司总部质检合格后，才在国内销售。
DprE1-IN-2-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-02-2018Print Date:Oct.-02-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :DprE1-IN-2Catalog No. :HY-100531CAS No. :1615713-87-51.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C19H24N6O2Molecular Weight:368.43CAS No. :1615713-87-54. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
硫辛酸注射液联合胰激肽原酶肠溶片对DPN_的临床疗效及生存质量的影响
DOI：10.16658/ki.1672-4062.2024.01.174硫辛酸注射液联合胰激肽原酶肠溶片对DPN的临床疗效及生存质量的影响王莉，朱海峰濉溪县中医医院内分泌科，安徽淮北235100[摘要]目的探讨硫辛酸注射液联合胰激肽原酶肠溶片对2型糖尿病周围神经病变（Diabetic Peripheral Neu⁃ropathy， DPN）患者的临床疗效、生存质量及安全性的影响。
方法选取2021年2月—2022年4月濉溪县中医医院60名DPN患者作为研究对象。
通过随机数表法分为两组，每组30例。
对照组采用常规治疗，观察组在对照组基础上加用硫辛酸注射液和胰激肽原酶肠溶片治疗。
比较两组患者的神经病变评分、神经电生理指标、生存质量评分、安全性指标和不良反应发生率。
结果治疗后，观察组神经病变评分（6.2±0.9）分低于对照组（7.6±1.1）分，差异有统计学意义（t=5.438，P<0.05）；观察组神经电生理指标、生存质量评分、安全性指标均优于对照组，差异有统计学意义（P均<0.05）；两组患者不良反应发生率比较，差异无统计学意义（P>0.05）。
结论硫辛酸注射液联合胰激肽原酶肠溶片对DPN患者有良好的临床疗效，能够改善神经功能、改善神经电生理指标、提高生存质量，且安全性高。
[关键词] 硫辛酸注射液；胰激肽原酶肠溶片；2型糖尿病周围神经病变；临床疗效[中图分类号] R587.2 [文献标识码] A [文章编号] 1672-4062（2024）01（a）-0174-05Effect of Lipoic Acid Injection Combined with Pancreatic Kininogenase Enteric-coated Tablets on Clinical Efficacy and Quality of Survival in DPN WANG Li, ZHU HaifengDepartment of Endocrinology, Suixi County Hospital of Traditional Chinese Medicine, Huaibei, Anhui Province, 235100 China[Abstract] Objective To investigate the effects of lipoic acid injection combined with pancreatic kininogenase enteric-coated tablets on the clinical efficacy, quality of survival and safety of patients with type 2 diabetic peripheral neuropathy (DPN). Methods 60 DPN patients admitted to Suixi County Hospital of Traditional Chinese Medicine from February 2021 to April 2022 were selected as the study objects. They were divided into two groups with 30 cases in each group by random number table method. The control group received conventional treatment, and the observation group was treated with lipoic acid injection and pancreatic kininogenase enteric-coated tablets on the basis of control group. Neuropathy score, neuroelectrophysiological index, quality of life score, safety index and incidence of adverse reactions were compared between the two groups. Results After treatment, the neuropathy score of observation group (6.2±0.9) points was lower than that of control group (7.6±1.1) points, and the difference was statistically significant (t= 5.438, P<0.05). Neuroelectrophysiological indexes, quality of survival scores and safety indexes of the observation group were better than those of the control group, and the differences were statistically significant (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Li⁃[作者简介]王莉（1982-），女，本科，主治医生，研究方向为糖尿病周围神经病变。
透析免疫沉淀试剂盒（50 次反应） （Pierce 交联 IP 试剂盒）说明书
说明书Pierce®交联 IP（免疫沉淀）试剂盒26147 2134.8货号描述26147 Pierce 交联 IP 试剂盒，包含足够进行 50 次免疫沉淀反应的试剂（每次使用 10 μL 树脂用于固定化抗体）试剂盒组分：Pierce 蛋白 A/G 加强型琼脂糖树脂，0.55 mL 固相树脂以 50%的浆液形式提供（例如，100 μL 50%的浆液含有 50 μL 固相树脂）。
20X交联缓冲液，25 mL，使用时稀释至1X，即为：0.01 M 磷酸钠盐缓冲液，0.15 M NaCl；pH 7.2 溶液DSS （辛二酸二琥珀酰亚胺酯），No-Weigh™（免称重）式，8X2mg 微管包装IP 裂解/洗涤缓冲液，2 X 50 mL，0.025 M Tris，0.15 M NaCl，0.001 M EDTA，1% NP-40，5%甘油；pH 7.4100X条件缓冲液，5 mL，中性 pH 缓冲液20XTris-缓冲盐溶液，25 mL，使用时稀释至1X，即为 0.025 M Tris，0.15 M NaCl；pH 7.2溶液洗脱缓冲液，50 mL，pH 2.8，含有伯胺非还原型上样缓冲液，（5X），5 mL，0.3M Tris•HCl，5% SDS，50%甘油，泳道标记示踪染料；pH 6.8Pierce 离心柱-带螺旋盖，100 个柱子，且包含相应配件微量离心收集管，2 mL，100 个微量离心样品管，1.5 mL，50 个Pierce 对照琼脂糖树脂（4％交联琼脂糖珠），2 mL 固相树脂以 50%的浆液形式提供（例如，100 μL 50%的浆液含有 50 μL 固相树脂）储存：收到试剂盒后将其储存于 4°C 。
DSS 置于 4°C 干燥保存。
试剂盒于室温运输。
产品简介Thermo Scienti c Pierce 交联 IP 试剂盒通过将抗体共价交联于蛋白 A/G 树脂从而高效地实现抗原免疫沉淀反应。
世界卫生组织儿童标准处方集
WHO Model Formulary for ChildrenBased on the Second Model List of Essential Medicines for Children 2009世界卫生组织儿童标准处方集基于2009年儿童基本用药的第二个标准目录WHO Library Cataloguing-in-Publication Data:WHO model formulary for children 2010.Based on the second model list of essential medicines for children 2009.1.Essential drugs.2.Formularies.3.Pharmaceutical preparations.4.Child.5.Drug utilization. I.World Health Organization.ISBN 978 92 4 159932 0 (NLM classification: QV 55)世界卫生组织实验室出版数据目录：世界卫生组织儿童标准处方集基于2009年儿童基本用药的第二个标准处方集1．基本药物 2.处方一览表 3.药品制备 4儿童 5.药物ISBN 978 92 4 159932 0 (美国国立医学图书馆分类：QV55)World Health Organization 2010All rights reserved. Publications of the World Health Organization can be obtained fromWHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: ******************). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the aboveaddress(fax:+41227914806;e-mail:*******************).世界卫生组织2010版权所有。
二甲双胍片联合德谷门冬胰岛素治疗难治性2型糖尿病的疗效研究
DOI：10.16658/ki.1672-4062.2023.22.092二甲双胍片联合德谷门冬胰岛素治疗难治性2型糖尿病的疗效研究李萌曦，赵忠涛，董焱连云港市赣榆区人民医院内分泌科，江苏连云港222100[摘要]目的探讨二甲双胍片联合德谷门冬胰岛素在难治性2型糖尿病中的诊疗意义。
方法选取2022年6月—2023年6月连云港市赣榆区人民医院接诊的82例难治性2型糖尿病患者为研究对象，采取随机数表法分为两组。
对照组（n=40）采用盐酸二甲双胍片+甘精胰岛素治疗，观察组（n=42）采用盐酸二甲双胍片+德谷门冬双胰岛素治疗。
比较两组患者血糖水平以及血糖波动等相关指标在治疗前后差异和并发症情况。
结果治疗前，两组患者血糖水平比较，差异无统计学意义（P>0.05）；治疗后，两组患者血糖均下降，且观察组血糖显著低于对照组，差异有统计学意义（P<0.05）；治疗前，两组患者血糖波动相关指标包括血糖均值、血糖水平标准差、最大血糖波动幅度、餐后血糖波动幅度比较，差异无统计学意义（P>0.05）；治疗后，两组患者血糖波动相关指标均改善，且观察组改善程度显著优于对照组，差异有统计学意义（P<0.05）；观察组并发症发生率低于对照组，差异有统计学意义（P<0.05）。
结论二甲双胍联合德谷门冬双胰岛素治疗效果更好，可明显改善难治性2型糖尿病患者血糖水平。
[关键词] 2型糖尿病；难治性；二甲双胍；德谷门冬双胰岛素[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2023）11（b）-0092-04Efficacy of Metformin Tablets Combined with Insulin Degludec and Insu⁃lin Aspart in the Treatment of Refractory Type 2 Diabetes MellitusLI Mengxi, ZHAO Zhongtao, DONG YanDepartment of Endocrinology, Ganyu District People's Hospital, Lianyungang, Jiangsu Province, 222100 China[Abstract] Objective To explore the significance of metformin tablets combined with insulin degludec and insulin as⁃part in the treatment of refractory type 2 diabetes mellitus. Methods A total of 82 patients with refractory type 2 diabe⁃tes mellitus treated in Ganyu District People's Hospital from June 2022 to June 2023 selected as the study objects and divided into two groups by random number table method. The control group (n=40) was treated with metformin hydro⁃chloride tablets + insulin glargine, and the observation group (n=42) was treated with metformin hydrochloride tablets+ Degu asparton double insulin. The differences and complications of blood glucose level, blood glucose fluctuation and other related indicators before and after treatment were compared between the two groups. Results Before treatment, there were no statistically significant differences in blood glucose levels between the two groups of patients (P>0.05). After treatment, blood glucose decreased in both groups, and the degree of blood glucose decrease in the observation group was significantly lower than that in the control group, the differences were statistically significant (P<0.05). Be⁃fore treatment, there were no statistically statistical significance differences in the indexes related to blood glucose fluctuation between the two groups, including mean blood glucose, standard deviation of blood glucose level, largest amplitude of glycemic excursion, and postprandial blood glucose fluctuation (P>0.05). After treatment, the relevant in⁃dexes of blood glucose fluctuation were improved in both groups, and the improvement degree of the observation group was significantly better than that of the control group, the differences were statistically significant (P<0.05). The com⁃plication rate of the observation group was lower than that of the control group, the difference was statistically signifi⁃cant (P<0.05). Conclusion Metformin combined with insulin degludec and insulin aspart is better, can significantly [作者简介]李萌曦（1989-），女，本科，主治医师，研究方向为内分泌科。
德谷门冬双胰岛素注射液治疗2_型糖尿病临床效果及安全性探讨
DOI：10.16658/ki.1672-4062.2023.17.098德谷门冬双胰岛素注射液治疗2型糖尿病临床效果及安全性探讨林生，谢平，陈予福州市长乐区人民医院内分泌科，福建福州350200[摘要]目的研究德谷门冬双胰岛素注射液治疗2型糖尿病的临床效果及安全性。
方法选取于2022年7月—2023年4月福州市长乐区人民医院收治的2型糖尿病患者98例为研究对象，采用随机抓阄法分为两组，每组49例。
两组均联用常规降糖药物治疗，对照组采用甘精胰岛素注射液治疗，观察组采用德谷门冬双胰岛素注射液治疗。
对比两组临床治疗效果、临床症状好转时间和胰岛素用量情况、糖代谢指标、胰岛素功能指标、不良反应发生情况、心血管不良事件发生情况。
结果观察组总有效率高于对照组，差异有统计学意义（P<0.05）。
观察组尿酮体转阴时间、血糖达标时间、胰岛素用量均优于对照组，差异有统计学意义（P< 0.05）。
观察组空腹血糖、餐后2 h血糖、糖化血红蛋白均低于对照组，差异有统计学意义（P<0.05）。
观察组胰岛β细胞功能指数高于对照组，胰岛素抵抗指数、空腹胰岛素低于对照组，差异有统计学意义（P<0.05）。
两组恶心呕吐、倦怠乏力、低血糖总发生率比较，差异无统计学意义（P>0.05）。
两组心绞痛、心力衰竭总发生率比较，差异无统计学意义（P>0.05）。
结论德谷门冬双胰岛素注射液治疗2型糖尿病临床效果显著优于甘精胰岛素注射液，但是治疗安全性无显著变化。
[关键词] 2型糖尿病；德谷门冬双胰岛素注射液；不良反应；心血管不良事件[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）09（a）-0098-04Discussion on the Clinical Effect and Safety of Insulin Degludec and Insu⁃lin Aspart Injection in the Treatment of Type 2 Diabetes MellitusLIN Sheng, XIE Ping, CHEN YuDepartment of Endocrinology, Changle District People's Hospital, Fuzhou, Fujian Province, 350200 China[Abstract] Objective To study the clinical effect and safety of insulin degludec and insulin aspart injection in the treatment of type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes admitted to Fuzhou Changle District People's Hospital from July 2022 to April 2023 were selected as the study objects and divided into two groups with 49 cases in each group by random lottery method. Both groups were treated with conventional hypoglycemic drugs, the control group was treated with insulin glargine injection, and the observation group was treated with Degu asparton double insulin injection. The clinical therapeutic effect, time of improvement of clinical symptoms, insulin dosage, glucose metabolism index, insulin function index, occurrence of adverse reactions and cardiovascular adverse events were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The time of urine ketone body turning negative, blood glucose reaching standard and insulin dosage in observation group were better than those in control group, and the differences were statistically significant (P<0.05). Fasting plasma glucose, 2-hour postprandial blood glucose and glycated hemoglobin in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The function index of islet β cells in observation group was higher than that in control group, the insulin resistance index and fasting insulin was lower than that in control group, the dif⁃ference was statistically significant (P<0.05). There was no statistically significant difference in the total incidence of [作者简介]林生（1981-），男，本科，副主任医师，研究方向为糖尿病及其并发症的相关临床研究。
细胞蛇的研究进展
2007年,英国牛津大学的刘骥陇等在研究果蝇U 小体和P 小体(U 小体和P 小体是真核生物细胞质中的无膜细胞器)的功能关系时,用4种针对Cup (P 小体中的一种蛋白质)的抗体,对雌性果蝇的卵巢组织进行免疫组织化学染色,染色结果除了预期标记上的P 小体外,还标记出了长条形的丝状结构[1]。
这种结构的形状和数量与纤毛很相似,导致当时以为在果蝇中找到了有纤毛的新细胞类型。
但后来的一系列实验表明,该结构与纤毛没有关系,于是将其命名为“细胞蛇”。
最初是抗Cup 抗体不纯产生假象,意外发现的细胞蛇,而采用亲和层析纯化后的抗Cup 抗体无法再DOI:10.16605/ki.1007-7847.2020.10.0258细胞蛇的研究进展收稿日期:2020-10-22;修回日期:2020-11-19;网络首发日期:2021-07-27基金项目:宁夏自然科学基金项目(2020AAC03179);国家自然科学基金资助项目(31560329)作者简介:李欣玲(1999—),女,广西贵港人,学生;*通信作者:俞晓丽(1984—),女,宁夏银川人,博士,副教授,主要从事干细胞与生殖生物学研究,E-mail:********************。
李欣玲,张樱馨,李进兰,潘文鑫,王彦凤,杨丽蓉,王通,俞晓丽*(宁夏医科大学生育力保持教育部重点实验室临床医学院基础医学院,中国宁夏银川750000)摘要:细胞蛇是近年来细胞生物学研究的热门方向之一,由于其在细胞的增殖、代谢和发育上具有一定的生物学功能,因此,对一些疾病如癌症等的临床诊断或治疗具有一定的指导意义。
细胞蛇是由三磷酸胞苷合成酶(cytidine triphosphate synthetase,CTPS)聚合而成的无膜细胞器,其形成过程及功能在不同类型的细胞中不尽相同。
例如:细胞蛇能促进癌细胞增殖,并使患者病情恶化;过表达的细胞蛇可抑制神经干细胞增殖,影响大脑皮层发育;在卵泡细胞中,细胞蛇相当于CTPS 的存储库,在卵子发生过程起到促进细胞增殖和代谢的作用。
2013年6月20日发布最新影响因子IF_完整版
Total Cites Impact5-Year ImmediacyArticles (linked to journal informationFactor Impact Index1439CA-CANCER J CLIN0007-923513722153.45988.5527.0425 6399NEW ENGL J MED0028-479324560551.65850.80712.667360 7457REV MOD PHYS0034-68613572044.98251.882 6.47846 1675CHEM REV0009-266511259641.29845.79514.335176 6266NAT REV GENET1471-00562335841.06336.4 6.31470 5693LANCET0140-673616692239.0636.4279.556313 6278NATURE0028-0836********.59738.1599.243869 6269NAT REV MOL CELL BIO1471-00723134137.16244.026 5.98565 668ANNU REV IMMUNOL0732-05821596336.55643.7428.42928 6247NAT MATER1476-11224634835.74942.3768.411141 6240NAT GENET1061-40368118335.20934.52 5.511225 6260NAT REV CANCER1474-175X326283539.361 6.33369 277ADV PHYS0001-8732484934.29431.1670.8577 6267NAT REV IMMUNOL1474-173********.12935.851 4.83165 6263NAT REV DRUG DISCOV1474-177********.07833.2058.65143 6232NAT BIOTECHNOL1087-01563872832.43832.1827.08792 1565CELL0092-867417876231.95734.366 6.499415 6272NAT REV NEUROSCI1471-003X2693831.67335.888 5.06562 6250NAT NANOTECHNOL1748-33872192031.1736.011 5.876121 7624SCIENCE0036-807550848931.02733.587 6.691832 6948PHYSIOL REV0031-93332253730.17438.707 2.53839 5608JAMA-J AM MED ASSOC0098-748412150429.97829.2738.504232 652ANNU REV BIOCHEM0066-41541942027.68131.964 4.31232 6252NAT PHOTONICS1749-48851399327.25431.5677.492120 7140PROG POLYM SCI0079-67001445726.38331.706 4.60756 3430IEEE ENG MED BIOL0739-5175291326.3038.0190 6245NAT IMMUNOL1529-29083246526.19925.005 4.961128 677ANNU REV PATHOL-MECH1553-4006232225.79419.915 6.38918 1599CELL STEM CELL1934-59091259325.31527.361 4.336122 5696LANCET ONCOL1470-20451700525.11721.856 6.536153 1678CHEM SOC REV0306-00124764624.89230.1817.997390 1500CANCER CELL1535-61082220024.75527.059 4.465114 5695LANCET NEUROL1474-44221516023.91722.959 4.47289 682ANNU REV PLANT BIOL1543-50081343823.65429.248 3.18527 6249NAT METHODS1548-70911924123.56523.231 4.404151 651ANNU REV ASTRON ASTR0066-4146824023.33334.261 2.21414 7125PROG MATER SCI0079-6425592123.19422.3337.21723 6912PHYS REP0370-157********.92922.99 6.69843 6248NAT MED1078-89565735022.86426.441 5.763186 6268NAT REV MICROBIOL1740-152********.4923.227 4.02969 6854PHARMACOL REV0031-69971033122.34522.114 2.33336 5764LIVING REV RELATIV1433-8351141722.33316.417 2.81811 6234NAT CHEM1755-4330865221.75723.02 5.532126 678ANNU REV PHARMACOL0362-1642720521.54321.6447.26926 15ACCOUNTS CHEM RES0001-48424211220.83324.633 5.295207 6233NAT CELL BIOL1465-73923222120.76120.691 3.97132 674ANNU REV NEUROSCI0147-006X1263820.61431.028 3.11526 5694LANCET INFECT DIS1473-30991047119.96618.095780 3581IMMUNITY1074-76133254619.79520.722 3.713164 680ANNU REV PHYSIOL0066-4278791419.54718.952 4.90521 6253NAT PHYS1745-24731800419.35219.367 6.854137 1098BEHAV BRAIN SCI0140-525X640218.57123.173 2.286144480J CLIN ONCOL0732-183X12867918.03817.255 4.836597 655ANNU REV CELL DEV BI1081-0706886617.98319.8060.78628 2458ECOL LETT1461-023X1753317.94918.495 1.403154 6221NANO TODAY1748-0132294417.68918.1920.78437 666ANNU REV GENET0066-4197677217.43621.7890.31232 1843CLIN MICROBIOL REV0893-85121205517.31319.065 2.21428 1422BRIT MED J1756-183********.21515.887.756328 6045MICROBIOL MOL BIOL R1092-2172907916.41717.718 1.51729 931ASTROPHYS J SUPPL S0067-00492476416.23814.437 3.074162 671ANNU REV MATER RES1531-7331525916.17914.4950.66718 8125TRENDS COGN SCI1364-66131571716.00816.845 4.05654 6356NEURON0896-62736952615.76616.403 2.603348 7191PSYCHOL BULL0033-29093081415.57519.676 2.31638 6271NAT REV NEUROL1759-4758229515.51813.994 1.65452 8126TRENDS ECOL EVOL0169-53472427915.38917.112 2.97476 7907SURF SCI REP0167-5729411515.33322.2817.758 6126MOL CELL1097-27654781815.2814.902 2.818296 683ANNU REV PSYCHOL0066-43081063515.26526.624 4.81822 7023PLOS MED1549-16761482015.25316.426 3.235115 6251NAT NEUROSCI1097-62564251915.25116.412 2.882228 1770CIRCULATION0009-732215228115.20215.385 2.98592 658ANNU REV CONDEN MA P1947-545462415.13915.139 5.13315 7122PROG ENERG COMBUST0360-1285476715.08917.778330 6262NAT REV CLIN ONCOL1759-4774276815.03114.931 2.660 6168MOL PSYCHIATR1359-41841268614.89713.985 3.879116 2532ENDOCR REV0163-769X1316614.87322.16 3.526 262ADV MATER0935-96489195214.82913.86 2.557867 458AM J PSYCHIAT0002-953X4273014.72114.396 2.574108 1583CELL METAB1550-41311243214.61917.551 3.25148 672ANNU REV MED0066-4219504314.60311.681 4.48635 389ALZHEIMERS DEMENT1552-5260290714.4838.672 2.2162 6236NAT CLIM CHANGE1758-678X84414.47214.5 2.65120 3122GENOME RES1088-90512885614.39714.104 3.416238 670ANNU REV MAR SCI1941-1405111414.36818.196 4.47621 5617JNCI-J NATL CANCER I0027-88743742414.33614.794 3.677124 95ACTA CRYSTALLOGR D0907-44491245314.1037.540.604182 2674EUR HEART J0195-668X3262914.09711.991 3.451273 4214J AM COLL CARDIOL0735-10977302114.08613.71 3.34427 597ANN INTERN MED0003-48194690513.97616.26 4.011176 7425REV GEOPHYS8755-1209646113.90613.333 2.0825 5849MAT SCI ENG R0927-796X485013.90218.9740.6676 5765LIVING REV SOL PHYS1614-496149813.833 1.8336 815ARCH GEN PSYCHIAT0003-990X3741213.77214.466 2.488125 529ANGEW CHEM INT EDIT1433-785122989413.73413.56 2.9592227 662ANNU REV ENTOMOL0066-4170877713.58914.047 3.09122 8134TRENDS NEUROSCI0166-22361788913.58214.466 2.31573 679ANNU REV PHYS CHEM0066-426X700213.36518.121 4.13829 7330REP PROG PHYS0034-48851022313.23214.937 3.55267 2892FEMS MICROBIOL REV0168-6445792613.23112.987 3.48152 4682J EXP MED0022-10076508813.21414.102 2.616190 8121TRENDS BIOCHEM SCI0968-00041564213.07612.005 2.40664 6219NANO LETT1530-69848843113.02514.132 2.4711078 6235NAT CHEM BIOL1552-44501081912.94815.6 3.715130 673ANNU REV MICROBIOL0066-4227844912.915.214 1.0825241ADV DRUG DELIVER REV0169-409X2156312.88815.431 1.488162 2296DEV CELL1534-58072030612.86114.091 2.174201 3076GASTROENTEROLOGY0016-50856040812.82112.835 3.424276 4471J CLIN INVEST0021-97389426412.81214.689 2.586394 7020PLOS BIOL1545-78852290812.6913.447 2.151152 654ANNU REV BIOPHYS1936-122X152912.6316.591 2.34626 1580CELL HOST MICROBE1931-3128610812.60913.567 2.943122 664ANNU REV FLUID MECH0066-4189675012.612.933 3.91323 3092GENE DEV0890-93695762712.44412.741 2.149249 657ANNU REV CLIN PSYCHO1548-5943204312.42214.073 1.44418 6241NAT GEOSCI1752-0894745112.36712.905 2.446148 7943SYST BIOL1063-51571141112.16913.316 2.80873 3590IMMUNOL REV0105-28961263412.15511.892 3.028106 55ACS NANO1936-0851*******.06212.524 1.941191 4200J ALLERGY CLIN IMMUN0091-67493607412.04710.108 2.752327 1010AUTOPHAGY1554-8627666112.0428.503 1.982114 3296HEPATOLOGY0270-91395012712.00311.4 2.169419 6275NAT STRUCT MOL BIOL1545-99932429911.90212.307 2.576184 7236Q REV BIOPHYS0033-5835227711.87512.163 1.2512 1761CIRC RES0009-73304644811.86111.028 2.465275 8137TRENDS PLANT SCI1360-138********.80811.675 2.1182 8124TRENDS CELL BIOL0962-89241103911.72112.095 2.32474 2544ENERG ENVIRON SCI1754-56921284911.65312.462 3.087473 2174CURR OPIN CELL BIOL0955-06741386611.4112.034 1.291110 6171MOL SYST BIOL1744-4292633511.3412.392 1.87757 215ADV APPL MECH0065-215696011.3337.1430.65 422AM J HUM GENET0002-92973468711.20212.512 2.188223 608ANN NEUROL0364-51343225611.19311.047 1.994173 462AM J RESP CRIT CARE1073-449X4971211.04110.919 2.705264 6264NAT REV ENDOCRINOL1759-5029202111.02511.479 1.85964 2070COORDIN CHEM REV0010-85452560111.01612.257 2.294136 653ANNU REV BIOMED ENG1523-9829315010.94614.5660.47419 4418J CELL BIOL0021-95257297410.82210.367 1.657283 7622SCI TRANSL MED1946-6234557410.75710.481 3.694219 3233GUT0017-57493071910.7329.988 3.821190 4213J AM CHEM SOC0002-786343128610.67710.237 2.1643099 1597CELL RES1001-0602702610.52610.216 2.84899 2789EUR UROL0302-28381708810.4768.083 4.043211 6265NAT REV GASTRO HEPAT1759-5045155210.4269.715 1.13666 6261NAT REV CARDIOL1759-5002167210.410.155 1.64751 661ANNU REV ECOL EVOL S1543-592X1490910.37516.8310.04821 6112MOL ASPECTS MED0098-2997301610.37510.821 1.46239 6115MOL BIOL EVOL0737-40383216810.35311.221 1.561294 3119GENOME BIOL1474-75961747810.2888.959 1.468154 1194BIOL REV1464-7931632610.25610.949 1.81153 7124PROG LIPID RES0163-7827389310.2510.69 1.58324 681ANNU REV PHYTOPATHOL0066-4286567610.22912.3130.69623 6255NAT PROD REP0265-0568660910.17810.072 2.38565 5735LEUKEMIA0887-69241825910.1648.692 2.401242 1505CANCER DISCOV2159-827463910.14310.143 2.97271 244ADV ENERGY MATER1614-6832199510.04310.05 2.118169 6237NAT COMMUN2041-1723732210.01510.02 2.096612 1360BRAIN0006-8950411899.91510.87 2.261280 4812J HEPATOL0168-8278222819.8588.897 2.863362516EMBO J0261-4189759509.8229.602 2.553333 7197PSYCHOL REV0033-295X213749.79711.342 1.22236 7141PROG QUANT ELECTRON0079-67277459.7868.29011 8129TRENDS GENET0168-9525107989.7729.325 2.10169 249ADV FUNCT MATER1616-301X347589.76510.342 1.815569 6273NAT REV RHEUMATOL1759-479019219.7459.318 1.44665 6692P NATL ACAD SCI USA0027-84245349519.73710.583 1.8933801 141ACTA NEUROPATHOL0001-6322116649.7348.562 2.565124 8122TRENDS BIOTECHNOL0167-779998339.669.289 1.61673 2132CSH PERSPECT BIOL1943-026439219.6310.3670.884155 1255BIOTECHNOL ADV0734-975066999.59911.85 1.248133 5984MED RES REV0198-632532979.5839.978 1.81137 8133TRENDS MOL MED1471-491459459.57110.142 1.48776 667ANNU REV GENOM HUM G1527-820423279.514.1250.620 921ASTRON ASTROPHYS REV0935-********.513.1947 2145CURR BIOL0960-9822431919.49410.445 2.307371 8131TRENDS IMMUNOL1471-490678509.4869.715 2.05178 2175CURR OPIN CHEM BIOL1367-593188699.4719.2560.98776 6377NEUROSCI BIOBEHAV R0149-7634129689.449.924 2.129147 7143PROG RETIN EYE RES1350-946235449.43910.188 1.57633 1828CLIN INFECT DIS1058-4838455569.3748.98 2.231523 2625EPIDEMIOL REV0193-936X29139.26919.051 3.07114 2571ENTERP INF SYST-UK1751-75755799.256 4.771 2.68222 6977PLANT CELL1040-4651390679.25110.125 1.526325 8136TRENDS PHARMACOL SCI0165-6147104179.2510.158 2.2774 1189BIOL PSYCHIAT0006-3223378409.2479.773 2.131251 6750PART FIBRE TOXICOL1743-897714719.1780.45544 676ANNU REV NUTR0199-988544909.15810.1880.920 2403DRUG RESIST UPDATE1368-764619659.1149.8130.8723 627ANN RHEUM DIS0003-4967270209.1118.351 2.308325 1278BLOOD0006-49711436709.069.338 2.1061251 6457NPG ASIA MATER1884-40493019.0428.556 2.41429 7129PROG NEUROBIOL0301-0082107149.03510.322 1.3275 1095BBA-REV CANCER0304-419X33349.03310.118 1.7560 4237J AM SOC NEPHROL1046-6673301328.9878.477 2.051195 8348WORLD PSYCHIATRY1723-861711938.974 6.413 2.42921 4133ISME J1751-736261298.9518.927 2.264208 8127TRENDS ENDOCRIN MET1043-276056138.9018.248 1.40574 3380HUM REPROD UPDATE1355-478656858.8479.512 1.88443 660ANNU REV EARTH PL SC0084-659746538.8339.861 1.51927 2246CYTOKINE GROWTH F R1359-610145878.8317.9190.58834 2186CURR OPIN IMMUNOL0952-791586898.7718.826 1.45284 2207CURR OPIN STRUC BIOL0959-440X101168.7389.02 1.45293 7728SLEEP MED REV1087-079229768.6818.26 1.94335 6371NEUROPSYCHOPHARMACOL0893-133X198828.6787.796 1.802248 1520CANCER RES0008-54721435228.658.576 1.539625 650ANNU REV ANAL CHEM1936-132711498.612.2830.69623 7022PLOS GENET1553-7404222128.5179.44 1.204691 7590SCHIZOPHRENIA BULL0586-7614116068.4868.934 1.699136 8058TOP CURR CHEM0340-102255078.456 6.205 4.27355 2202CURR OPIN PLANT BIOL1369-526694618.4559.221 1.22996 8132TRENDS MICROBIOL0966-842X82268.4348.09 2.15372 8038THORAX0040-6376177868.3767.808 2.371159 1577CELL DEATH DIFFER1350-9047145518.3718.395 2.2791901676CHEM SCI2041-652048458.3148.33 2.771458 6474NUCLEIC ACIDS RES0305-10481187158.2788.055 2.2051425 7656SEMIN LIVER DIS0272-808735158.274 6.8240.64937 6352NEUROLOGY0028-3878744088.2498.397 1.816527 1663CHEM MATER0897-4756746518.2387.627 1.123576 2190CURR OPIN MICROBIOL1369-527476958.238.104 1.06199 4330J AUTOIMMUN0896-841141688.145 6.075 1.30698 7026PLOS PATHOG1553-7374197438.1368.917 1.306627 2460ECOL MONOGR0012-961584478.0858.1290.84626 5271J PHOTOCH PHOTOBIO C1389-556720268.06911.9520.7516 3031FRONT NEUROENDOCRIN0091-302228427.98510.876 1.79329 5714LASER PHOTONICS REV1863-888015497.9768.779 2.44243 1000AUTOIMMUN REV1568-997250027.975 6.069 1.656163 6257NAT PROTOC1754-2189169227.9611.743 1.362174 6270NAT REV NEPHROL1759-506113547.9437.409 1.20663 6918PHYS REV LETT0031-90073621857.9437.435 2.176**** ****KIDNEY INT0085-2538380947.916 6.968 2.603234 2311DIABETES0012-1797461587.8958.611 1.542347 2172CURR OPIN BIOTECH0958-166995017.869.006 1.328131 6230NANOTOXICOLOGY1743-539013877.8447.758 1.24374 1374BRAIN STRUCT FUNCT1863-265312597.837 6.821 1.38255 1794CLIN CANCER RES1078-0432657047.8377.827 1.814665 7730SMALL1613-6810181377.8238.084 1.429457 1372BRAIN RES REV0165-017389037.8188.7860 8028THERANOSTICS1838-76404287.8067.806 1.98993 2517EMBO MOL MED1757-467612907.7959.39 1.698106 7054POLYM REV1558-372411557.79410.021 1.45511 6855PHARMACOL THERAPEUT0163-7258106557.7938.736 1.343108 1516CANCER METAST REV0167-765950167.78710.0880.85368 2312DIABETES CARE0149-5992490257.7357.555 2.234427 5846MASS SPECTROM REV0277-703739447.7359.924228 5716LASER PHYS LETT1612-201141167.714 4.9740.703158 7138PROG PHOTOVOLTAICS1062-799545357.7127.023 3.223112 7845STEM CELLS1066-5099182537.7018.368 1.297269 3374HUM MOL GENET0964-6906360417.6927.541 1.554478 7614SCI SIGNAL1937-914551687.6487.603 1.478182 4543J CONTROL RELEASE0168-3659297557.6338.078 1.136501 3024FRONT ECOL ENVIRON1540-929543167.61510.061 1.2560 7446REV MED VIROL1052-927617587.6157.024 1.35728 1204BIOMATERIALS0142-9612697927.6048.496 1.597898 5231J PATHOL0022-3417144687.585 6.928 2.376173 415AM J GASTROENTEROL0002-9270275217.5537.019 2.074188 4970J MAMMARY GLAND BIOL1083-302121207.524 5.838 1.225 656ANNU REV CHEM BIOMOL1947-54383317.5127.512 1.04522 7235Q REV BIOL0033-577033127.57.9040.1119 4037INT MATER REV0950-660822557.487.149 1.18816 876ARTHRITIS RHEUM-US0004-3591452007.4777.63 1.659411 1698CHEMSUSCHEM1864-563150567.4757.951 1.189286 2183CURR OPIN GENET DEV0959-437X81787.478.209 1.53880 7647SEMIN CANCER BIOL1044-579X42997.4367.107 2.22653 6140MOL ECOL RESOUR1755-098X47367.432 4.150.848132 7145PROG SOLID STATE CH0079-678614747.429 3.33806 675ANNU REV NUCL PART S0163-899821167.48.7770.73719 3210GONDWANA RES1342-937X43947.396 6.171 2.1341576220NANO RES1998-012430317.3927.8010.97996 615ANN ONCOL0923-7534228057.384 6.473 1.214541 6552ONCOGENE0950-9232605267.3577.18 2.218458 2436EARTH-SCI REV0012-825262047.3398.759 1.04981 2193CURR OPIN NEUROBIOL0959-4388114297.3358.165 1.111135 5064J MOL CELL BIOL1674-27886517.3088.271 1.75737 5298J PINEAL RES0742-309849567.304 5.451 1.10992 2593ENVIRON HEALTH PERSP0091-6765301117.267.522 1.56268 258ADV IMMUNOL0065-277623257.2568.020.87131 6132MOL CELL PROTEOMICS1535-9476142017.2518.051 1.532310 7206PSYCHOTHER PSYCHOSOM0033-319027617.23 5.825 1.26926 3201GLOBAL ECOL BIOGEOGR1466-822X52767.2237.284 1.935108 695ANTIOXID REDOX SIGN1523-0864118627.1897.548 1.991222 2518EMBO REP1469-221X105747.1897.396 1.68799 1796CLIN CHEM0009-9147265827.1497.192 2.737152 7146PROG SURF SCI0079-681619047.1369.140.27311 223ADV CARBOHYD CHEM BI0065-23188337.133 5.8460.754 2812EXERC IMMUNOL REV1077-55524387.053 5.2560.1258 6172MOL THER1525-0016127597.041 6.457 1.676219 6190MUCOSAL IMMUNOL1933-021*******.119 1.65767 3826INT J EPIDEMIOL0300-577114451 6.9827.001 3.281128 4205J AM ACAD CHILD PSY0890-856716470 6.977.148 2.0196 6223NANOMED-NANOTECHNOL1549-96343097 6.937.647 1.263160 2228CURR TOP DEV BIOL0070-21532246 6.912 6.4670.76242 6685P IEEE0018-921918840 6.9117.6940.697195 3200GLOBAL CHANGE BIOL1354-101318398 6.917.819 1.3297 6534OCEANOGR MAR BIOL0078-32182142 6.9099.8790.56 5139J NEUROSCI0270-6474160915 6.9087.8690.9781668 3362HUM BRAIN MAPP1065-947113379 6.8787.032 1.451226 3398HYPERTENSION0194-911X32323 6.873 6.984 1.588342 6518OBES REV1467-78815154 6.877.021 1.436101 6008METAB ENG1096-71762855 6.859 6.696 1.34772 1864CLIN PHARMACOL THER0009-923614263 6.846 6.349 1.995200 1627CEREB CORTEX1047-321121409 6.8287.463 2.05258 3224GREEN CHEM1463-926215554 6.828 6.992 1.269449 6929PHYS TODAY0031-92283738 6.762 5.263 1.51437 275ADV ORGANOMET CHEM0065-3055841 6.758.94103 6949PHYSIOLOGY1548-92132500 6.758.388 1.13829 6407NEW PHYTOL0028-646X26842 6.736 6.888 1.373378 929ASTROPHYS J0004-637X191940 6.733 5.945 2.0473075 1764CIRC-CARDIOVASC GENE1942-325X1641 6.728 6.398 1.17182 6921PHYS REV X2160-3308414 6.711 6.737 2.22571 6158MOL ONCOL1574-78911193 6.701 6.3790.91760 1768CIRC-HEART FAIL1941-32892007 6.684 6.67 1.41993 1309BMC MED1741-70152691 6.679 6.413 1.275109 1820CLIN GASTROENTEROL H1542-35658295 6.648 6.108 1.458179 6561ONCOTARGET1949-25531450 6.636 6.636 1.316114 2177CURR OPIN COLLOID IN1359-02944670 6.6297.0360.88443 2862EXPERT REV MOL MED1462-39941734 6.6230.78919 1417BRIT J PSYCHIAT0007-125021472 6.6067.112 1.872117 1019B AM METEOROL SOC0003-000711821 6.5917.704 2.48778 5280J PHYS CHEM LETT1948-71858575 6.585 6.651 1.301632 6902PHYS LIFE REV1571-0645659 6.583 6.699.45511 6990PLANT J0960-741232497 6.5827.113 1.5333456997PLANT PHYSIOL0032-088962407 6.5557.084 1.313469 5605JACC-CARDIOVASC INTE1936-87983378 6.552 6.834 1.603126 2396DRUG DISCOV TODAY1359-64468855 6.551 6.89 1.177158 271ADV MICROB PHYSIOL0065-29111006 6.545 6.267 1.25 1766CIRC-CARDIOVASC INTE1941-76401534 6.543 6.239 1.23797 1292BMC BIOL1741-70072631 6.531 6.384 1.69559 405AM J CLIN NUTR0002-916548233 6.5047.196 1.2325 2325DIABETOLOGIA0012-186X24906 6.487 6.772 1.749339 6150MOL INTERV1534-03841243 6.4818.0310 1490CAN MED ASSOC J0820-394611869 6.4657.53 1.766124 4906J INTERN MED0954-******** 6.455 5.913 1.609110 4465J CLIN ENDOCR METAB0021-972X68170 6.43 6.568 1.087809 6203MUTAT RES-REV MUTAT1383-57422736 6.4268.202122 6368NEUROPSYCHOL REV1040-73081611 6.427.5260.86229 353AIDS0269-937023034 6.407 6.131 1.679265 8059TOP ORGANOMETAL CHEM1436-60021152 6.384 1.76221 1643CHEM COMMUN1359-7345122728 6.378 6.226 1.533173 1557CATAL REV0161-49402529 6.37510.1750.8899 2780EUR RESPIR J0903-193625962 6.355 6.32 1.82317 222ADV CANCER RES0065-230X1890 6.351 5.5120.57121 8074TRAC-TREND ANAL CHEM0165-99367327 6.351 6.7610.92138 930ASTROPHYS J LETT2041-820545993 6.345 1.687670 7279RADIOLOGY0033-841945413 6.339 6.7380.832381 873ARTERIOSCL THROM VAS1079-564231851 6.338 6.986 1.097370 636ANN SURG0003-493236761 6.3298.264 1.15301 6973PLANT BIOTECHNOL J1467-76443136 6.279 5.813 1.04101 6139MOL ECOL0962-108330411 6.275 6.792 1.369445 2110CRIT REV TOXICOL1040-84442955 6.253 5.9720.94335 6339NEUROIMAGE1053-811961770 6.2527.063 1.2911222 2595ENVIRON INT0160-41209059 6.248 6.1220.935199 5339J PSYCHIATR NEUROSCI1180-48822253 6.242 6.473 1.64734 6226NANOSCALE2040-33647835 6.233 6.262 1.1671015 7886STUD MYCOL0166-06161237 6.231 6.813 4.1676 6869PHILOS T R SOC B0962-843626581 6.237.298 3.522289 2310DEVELOPMENT0950-199151191 6.208 6.888 1.258434 7648SEMIN CELL DEV BIOL1084-95215613 6.202 6.51 1.034116 3764INT J CANCER0020-713644529 6.198 5.474 1.39738 4915J INVEST DERMATOL0022-202X23976 6.193 6.065 1.898264 471AM J TRANSPLANT1600-613516088 6.192 6.014 1.506348 6318NEURO-ONCOLOGY1522-85173845 6.18 5.9470.694157 231ADV COLLOID INTERFAC0001-86867115 6.1698.01 1.3250 6320NEUROBIOL AGING0197-458015479 6.166 6.098 1.583537 5604JACC-CARDIOVASC IMAG1936-878X2977 6.164 6.703 1.717113 2080CORTEX0010-94525265 6.161 5.042 2.745106 7864STROKE0039-249952524 6.158 6.831 1.086567 1640CHEM BIOL1074-55219695 6.157 6.097 1.486144 6621ORG LETT1523-706073440 6.142 5.563 1.5721608 4378J BONE MINER RES0884-043122111 6.128 6.227 1.101257 6165MOL PLANT1674-20522346 6.126 5.77 1.585118 2094CRIT CARE MED0090-349332733 6.124 6.401 2.614363 2371DIVERS DISTRIB1366-95164336 6.122 5.7430.935107 1863CLIN PHARMACOKINET0312-******** 6.109 5.4860.98154 8313WHO TECH REP SER0512-******** 6.1 3.2560.35714 8039THROMB HAEMOSTASIS0340-624517392 6.094 4.782 1.3462465510J THROMB HAEMOST1538-793314645 6.081 6.176 1.17265 5876MATER TODAY1369-70213769 6.0718.677 1.97744 1578CELL DEATH DIS2041-48891481 6.044 6.0440.565191 4548J COSMOL ASTROPART P1475-751613656 6.036 5.295 2.387555 1523CANCER TREAT REV0305-73724233 6.024 6.246 1.458107 7131PROG NUCL MAG RES SP0079-65651993 6.022 6.065 1.38918 1285BLOOD REV0268-960X17706 6.6620.76939 7877STRUCTURE0969-212612441 5.994 6.081 1.466191 2519EMERG INFECT DIS1080-604021567 5.993 6.312 1.689244 322AGEING RES REV1568-16371965 5.953 6.549 1.43941 7706SIAM REV0036-14455051 5.9528.4140.40922 1763CIRC-ARRHYTHMIA ELEC1941-31492173 5.947 6.434 1.175143 2108CRIT REV SOLID STATE1040-8436744 5.9477.368110 1543CARDIOVASC RES0008-636320689 5.94 6.113 1.689222 3241HAEMATOL-HEMATOL J0390-607811392 5.935 6.002 1.454251 7654SEMIN IMMUNOL1044-53233190 5.9267.250.89146 6031METHODS ECOL EVOL2041-210X822 5.92460.854123 203ADDICT BIOL1355-62151977 5.914 5.322 1.01193 1081BASIC RES CARDIOL0300-84283292 5.904 5.362 1.16772 6390NEUROTHERAPEUTICS1933-72131923 5.904 5.720.90563 381ALLERGY0105-453812173 5.883 5.983 1.58193 4422J CELL SCI0021-953340261 5.877 6.375 1.032535 1391BREAST CANCER RES1465-542X7547 5.872 6.2640.82172 1528CARBON0008-622332742 5.868 6.35 1.197674 2915FISH FISH1467-29601846 5.8557.326 1.53826 1699CHEST0012-369244596 5.854 6.42 3.394307 4871J INFECT DIS0022-189942783 5.848 5.914 1.556493 2189CURR OPIN LIPIDOL0957-96723620 5.839 5.7380.92264 6966PIGM CELL MELANOMA R1755-14713385 5.839 5.434 1.39768 1685CHEM-EUR J0947-653960788 5.831 5.623 1.2411916 717APPL CATAL B-ENVIRON0926-337323011 5.825 6.0310.965480 4486J CLIN PSYCHIAT0160-668917639 5.812 5.6390.726157 1765CIRC-CARDIOVASC IMAG1941-96511650 5.795 6.579 1.17984 5924MAYO CLIN PROC0025-61969444 5.79 5.638 1.44109 4413J CATAL0021-951734516 5.787 6.249 1.025284 5164J NUCL MED0161-550521262 5.774 6.4020.934243 2597ENVIRON MICROBIOL1462-291213228 5.756 5.943 1.455242 2626EPIDEMIOLOGY1044-39838979 5.738 6.241 2.12588 8328WIRES COMPUT MOL SCI1759-0876570 5.738 5.738 3.51856 2539ENDOSCOPY0013-726X8401 5.735 5.355 1.514144 4048INT REV IMMUNOL0883-******* 5.733 4.140.44829 324AGING CELL1474-97184134 5.705 6.415 1.485130 2885FASEB J0892-663839540 5.704 6.222 1.13462 1895COCHRANE DB SYST REV1469-493X34230 5.703 6.5120.728977 5027J MED GENET0022-259311563 5.703 5.793 1.353116 5687LAB CHIP1473-019716485 5.697 6.136 1.256617 510ANAL CHEM0003-270096794 5.695 5.7690.9481479 6697P ROY SOC B-BIOL SCI0962-845237539 5.683 5.832 1.224624 8330WIRES NANOMED NANOBI1939-5116983 5.681 6.34 1.08547 1767CIRC-CARDIOVASC QUAL1941-77051551 5.658 5.647 1.43100 7369RETROVIROLOGY1742-46903084 5.657 4.857 1.505107 6713PAIN0304-395929370 5.644 6.125 1.264269 3917INT J NEUROPSYCHOPH1461-14574003 5.641 5.0920.805123 1530CARCINOGENESIS0143-333421223 5.635 5.5570.9553106383NEUROSCIENTIST1073-85843259 5.633 6.417 1.35645 7327RENEW SUST ENERG REV1364-032110347 5.627 6.5770.803584 6321NEUROBIOL DIS0969-996111288 5.624 5.482 1.493296 5925MBIO2150-75111260 5.621 5.621 1.536151 4817J HIGH ENERGY PHYS1126-670852898 5.618 4.712 2.6581861 1589CELL MOL LIFE SCI1420-682X17974 5.615 6.359 1.072290 5022J MED CHEM0022-262359227 5.614 5.383 1.225890 1362BRAIN BEHAV IMMUN0889-15916137 5.612 5.698 1.082147 6124MOL CANCER THER1535-716314654 5.599 5.72 1.201259 1873CLIN REV ALLERG IMMU1080-05491685 5.59 3.955 1.30662 7194PSYCHOL MED0033-291716680 5.587 6.1480.913230 2098CRIT REV BIOCHEM MOL1040-92382729 5.5788.032 1.23330 6583OPHTHALMOLOGY0161-642026007 5.563 5.777 1.065354 3107GENET MED1098-36004119 5.56 5.035 1.554121 1259BIOTECHNOL BIOFUELS1754-6834903 5.552 6.4590.35288 2401DRUG METAB REV0360-25322342 5.538 5.843 1.2516 291ADV SYNTH CATAL1615-415015502 5.535 5.323 1.109404 5793MACROMOLECULES0024-929797921 5.521 5.209 1.0941069 6176MON NOT R ASTRON SOC0035-871196083 5.521 5.009 1.7942574 4853J IMMUNOL0022-1767129339 5.52 5.6730.951289 7791SPACE SCI REV0038-63087134 5.519 5.1060.921114 8135TRENDS PARASITOL1471-49224819 5.513 4.878 1.11470 943ATMOS CHEM PHYS1680-731622919 5.51 5.556 1.176723 3765INT J CARDIOL0167-527312371 5.509 4.125 1.681326 2133CSH PERSPECT MED2157-1422211 5.5 5.5 1.099142 6511NUTR RES REV0954-******** 5.5 5.2020.11817 3323HIPPOCAMPUS1050-96318046 5.492 5.484 1.603184 2798EUROSURVEILLANCE1560-79175236 5.491 1.34188 3492IEEE T FUZZY SYST1063-67066237 5.484 4.8850.58193 6155MOL NEUROBIOL0893-******** 5.471 5.5350.782101 6289NEOPLASIA1522-80025715 5.47 5.077 1.208120 4096INVEST RADIOL0020-99965353 5.46 4.444 1.392102 1090BBA-GENE REGUL MECH1874-93994518 5.456 4.338 1.217129 2201CURR OPIN PHARMACOL1471-48925198 5.443 6.4470.765102 50ACS CHEM BIOL1554-89293417 5.442 5.478 1.387230 2206CURR OPIN SOLID ST M1359-02862508 5.4387.3290.91323 1248BIOSENS BIOELECTRON0956-566322068 5.437 5.389 1.105448 4592J ECOL0022-047713938 5.431 6.199**** ****BIOESSAYS0265-92478695 5.423 4.814 1.291134 4448J CHILD PSYCHOL PSYC0021-963012841 5.422 6.2350.976127 2194CURR OPIN NEUROL1350-75404449 5.416 5.0350.80497 4427J CEREBR BLOOD F MET0271-678X14671 5.398 5.66 1.093194 4439J CHEM THEORY COMPUT1549-961811067 5.389 5.936 1.067507 7655SEMIN IMMUNOPATHOL1863-22971214 5.379 5.668 1.6958 6128MOL CELL BIOL0270-730667211 5.372 5.745 1.036415 1200BIOMACROMOLECULES1525-779724209 5.371 5.750.721480 4261J ANTIMICROB CHEMOTH0305-745320364 5.338 4.686 1.257428 4466J CLIN EPIDEMIOL0895-435615399 5.332 5.120.711149 5284J PHYS G NUCL PARTIC0954-******** 5.326 2.812 1.37184 1165BIOINFORMATICS1367-480351753 5.323 6.9110.729728 3052FUNGAL DIVERS1560-27451665 5.319 4.2 1.73653 6993PLANT MOL BIOL REP0735-******** 5.319 4.020.293157 2152CURR GENE THER1566-52321362 5.318 4.3220.6141 4224J AM MED DIR ASSOC1525-86102480 5.302 3.912 1.3431781398BRIEF BIOINFORM1467-54633073 5.2987.51 1.27658 426AM J KIDNEY DIS0272-638619101 5.294 5.417 1.724199 2813EXERC SPORT SCI REV0091-63312207 5.283 4.841127 5781MABS-AUSTIN1942-0862765 5.275 4.8240.78565 3012FREE RADICAL BIO MED0891-584931156 5.271 5.969 1.033450 49ACS CATAL2155-54351461 5.265 5.265 1.222315 2533ENDOCR-RELAT CANCER1351-00884611 5.261 5.1720.73494 6224NANOMEDICINE-UK1743-58892713 5.26 6.2360.746114 4068INTENS CARE MED0342-464214780 5.258 5.036 1.074215 2611ENVIRON SCI TECHNOL0013-936X92385 5.257 5.8650.7921608 4364J BIOMED NANOTECHNOL1550-70332198 5.256 4.366 1.491108 6110MODERN PATHOL0893-395210184 5.253 5.058 1.371175 224ADV CATAL0360-05641399 5.25 5.28602 226ADV CHEM PHYS0065-23852306 5.25 4.250.71746 1066B WORLD HEALTH ORGAN0042-968611151 5.25 6.076 1.04295 2708EUR J HEART FAIL1388-98425824 5.247 4.738 1.469147 2770EUR PHYS J C1434-604411003 5.247 3.603 2.222406 1576CELL CYCLE1538-410115668 5.243 4.806 1.079444 4679J EXP BOT0022-095724541 5.242 5.5420.903493 7814SPORTS MED0112-16427069 5.237 5.7550.64164 3202GLOBAL ENVIRON CHANG0959-37804587 5.236 6.9010.88285 7047POLYM CHEM-UK1759-99543328 5.231 5.231 1.305397 3018FRONT AGING NEUROSCI1663-4365392 5.224 5.1690.72733 3933INT J OBESITY0307-056518052 5.221 5.522 1.174213 852ARCH TOXICOL0340-57614824 5.215 3.990.94149 3376HUM MUTAT1059-779411082 5.213 5.761 1.754224 3077GASTROINTEST ENDOSC0016-510718497 5.21 5.276 2.32297 1524CANCER-AM CANCER SOC0008-543X62757 5.201 5.693 1.108674 2205CURR OPIN RHEUMATOL1040-87113701 5.191 4.256 1.04589 1688CHEMCATCHEM1867-38802718 5.181 5.3070.941255 2315DIABETES OBES METAB1462-89024587 5.181 4.415 1.491173 2463ECOLOGY0012-965850217 5.175 6.3720.583283 3497IEEE T IND ELECTRON0278-004617404 5.165 5.0780.943470 528ANESTHESIOLOGY0003-302222547 5.163 5.302 1.959219 5065J MOL CELL CARDIOL0022-282811674 5.148 5.034 1.478232 7200PSYCHONEUROENDOCRINO0306-45309603 5.137 5.926 1.091198 6978PLANT CELL ENVIRON0140-779114009 5.135 5.861 1.639158 6122MOL CANCER1476-45984995 5.134 5.0970.3686 6849PHARMACOGENOMICS J1470-269X2084 5.134 4.455 1.12365 2444ECOGRAPHY0906-******** 5.124 5.7910.925120 2179CURR OPIN DRUG DISC1367-67331825 5.121 4.1080 3657INFLAMM BOWEL DIS1078-09988279 5.119 5.233 1.161261 6801PEDIATRICS0031-400559035 5.119 5.930.951687 2702EUR J EPIDEMIOL0393-******** 5.118 4.1160.49489 2729EUR J NUCL MED MOL I1619-707010881 5.114 4.821 1.202198 4805J HEART LUNG TRANSPL1053-24987139 5.112 3.6270.975159 5104J NATL COMPR CANC NE1540-14051890 5.1120.522115 7318REMOTE SENS ENVIRON0034-425724105 5.103 6.1440.987388 7724SLEEP0161-810514444 5.1 6.175 1.068162 2099CRIT REV BIOTECHNOL0738-******** 5.095 5.9660.95221 604ANN MED0785-38903665 5.094 4.640.76397 74ACTA BIOMATER1742-706110169 5.093 5.3780.903453 1575CELL COMMUN SIGNAL1478-811X520 5.0930.20539 7499RNA1355-838211854 5.088 5.43 1.01201920ASTRON ASTROPHYS0004-6361101305 5.084 4.422 1.4511892 1404BRIT J CANCER0007-092038414 5.082 5.2060.827561 5569J VIROL0022-538X93028 5.076 4.893 1.2581559 1831CLIN J AM SOC NEPHRO1555-90418449 5.068 5.445 1.1240 1415BRIT J PHARMACOL0007-118828119 5.067 4.898 1.288539 3198GLIA0894-149110371 5.066 5.406 1.38166 2105CRIT REV MICROBIOL1040-841X1335 5.065 5.615 1.09521 2675EUR HEART J SUPPL1520-765X977 5.065 1.817 1.910 2681EUR J CANCER0959-804921316 5.061 5.2570.991343 208ADV AGRON0065-21132753 5.06 5.5120.45824 5336J PROTEOME RES1535-389317943 5.056 5.2230.882544 3916INT J NEURAL SYST0129-0657992 5.054 3.6460.45735 1975COMPR REV FOOD SCI F1541-43371046 5.053 4.7920.26730 3273HEART RHYTHM1547-52717449 5.045 4.719 2.089237 1775CLADISTICS0748-30073315 5.043 6.183 1.86730 7737SOC COGN AFFECT NEUR1749-50161980 5.042 6.78 1.347101 3173GEOSCI MODEL DEV1991-959X626 5.03 4.50.84691 6186MRS BULL0883-******** 5.024 5.590.569116 3269HEART1355-603713857 5.014 4.769 1.667243 48ACS APPL MATER INTER1944-82448635 5.008 5.040.683953 2491ELECTROANAL CHEM0070-977837757.50.254 216ADV APPL MICROBIOL0065-21641233 4.974 4.7840.33321 4045INT REV CEL MOL BIO1937-6448825 4.973 4.9440.40849 2713EUR J IMMUNOL0014-298020974 4.97 4.7680.739322 663ANNU REV ENV RESOUR1543-59381402 4.9687.25018 923ASTRON J0004-625634668 4.965 4.571 1.162334 6154MOL MICROBIOL0950-382X37172 4.961 5.099 1.123359 2351DIS MODEL MECH1754-84031212 4.959 5.0090.98988 1407BRIT J HAEMATOL0007-104820668 4.942 4.7260.891266 4497J COMB CHEM1520-47662925 4.933 3.1020 5789MACROMOL RAPID COMM1022-133612103 4.929 4.6180.916261 5129J NEUROL NEUROSUR PS0022-305023923 4.924 5.144 1.69187 2628EPIGENETICS-US1559-22942289 4.92 4.8810.773150 4050INT REV PHYS CHEM0144-235X1524 4.92 5.595 2.23113 1119BEST PRACT RES CL EN1521-690X2576 4.912 5.1810.25866 1091BBA-MOL BASIS DIS0925-44396277 4.91 4.932 1.248202 5451J STAT SOFTW1548-76602629 4.91 5.9070.75377 5356J R SOC INTERFACE1742-56895016 4.907 5.1650.806320 4206J AM ACAD DERMATOL0190-962219760 4.906 4.5150.896280 1518CANCER PREV RES1940-62073114 4.891 5.126 1.401142 2187CURR OPIN INFECT DIS0951-******** 4.87 4.610.83987 2846EXPERT OPIN DRUG DEL1742-52472829 4.869 5.1330.495103 469AM J SURG PATHOL0147-518516422 4.868 4.8570.798223 7021PLOS COMPUT BIOL1553-735811758 4.867 5.9390.824507 6837PFLUG ARCH EUR J PHY0031-67689307 4.866 3.9280.853129 2810EVOLUTION0014-382030585 4.864 5.4020.939313 4347J BIOGEOGR0305-027010682 4.863 4.979 1.399183 3042FUNCT ECOL0269-84639681 4.861 5.3930.882153 2231CURR TOP MICROBIOL0070-217X4958 4.86 4.744 5.05319 1875CLIN SCI0143-52218069 4.859 4.843 1.2110 174ACTA PSYCHIAT SCAND0001-690X11048 4.857 4.625198 386ALTERN MED REV1089-51591288 4.857 5.0340.56 250ADV GENET0065-26601198 4.85 4.102010 4253J ANIM ECOL0021-879012354 4.841 5.1660.881134。
德谷门冬双胰岛素注射液治疗2_型糖尿病的疗效及安全性研究
DOI：10.16658/ki.1672-4062.2023.19.084德谷门冬双胰岛素注射液治疗2型糖尿病的疗效及安全性研究戴卉，张开凤，朱凤丽江苏省镇江市丹徒区人民医院内分泌科，江苏镇江212000[摘要]目的探讨德谷门冬双胰岛素注射液在2型糖尿病中的效果以及安全性。
方法选取2022年1月—2023年7月江苏省镇江市丹徒区人民医院收治的62例2型糖尿病患者为研究对象，按随机数表法分为对照组（n=31）和观察组（n=31）。
对照组患者接受门冬胰岛素30注射液治疗，观察组患者接受德谷门冬双胰岛素注射治疗。
对比两组患者临床疗效、血糖变化和不良反应发生率。
结果观察组治疗有效为96.77%，高于对照组的77.42%，差异有统计学意义（χ2=5.167，P=0.023）。
治疗前，两组患者血糖水平比较，差异无统计学意义（P>0.05）；治疗后，两组患者血糖水平均改善，且观察组血糖指标低于对照组，差异有统计学意义（P< 0.05）。
观察组不良反应发生率低与对照组，差异有统计学意义（P<0.05）。
结论德谷门冬双胰岛素的应用可以明显改善2型糖尿病患者血糖水平，疗效更为确切，且安全性更高，不会增加用药后不良反应。
[关键词] 2型糖尿病；德谷门冬双胰岛素；门冬胰岛素30注射液；安全性[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2023）10（a）-0084-04Study on the Efficacy and Safety of Insulin Degludec and Insulin Aspart Injection in the Treatment of Type 2 Diabetes MellitusDAI Hui, ZHANG Kaifeng, ZHU FengliDepartment of Endocrinology, Zhenjiang Dantu District People's Hospital, Zhenjiang, Jiangsu Province, 212000 China [Abstract] Objective To explore the effect and safety of insulin degludec and insulin aspart injection in type 2 diabe⁃tes mellitus.Methods 62 patients of type 2 diabetes mellitus patients admitted to Zhenjiang Dantu District People's Hospital, Jiangsu Province from January 2022 to July 2023 were selected as study objects and divided into the control group (n=31) and the observation group (n=31) by taking the random number table method. The patients in the control group were treated with insulin aspart 30 injection and the patients in the observation group were treated with insulin degludec and insulin aspart injection. Compared the clinical efficacy, the changes in blood glucose and the incidence of adverse reactions between the two groups of patients.Results The treatment effectiveness of the observation group was 96.77%, which was higher than that of the control group, which was 77.42%, and the difference was statistically significant (χ2=5.167, P=0.023). There was no statistically significant difference in blood glucose levels between the two groups before treatment (P>0.05). After treatment, blood glucose levels improved in both groups, and the level of blood glucose in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05).Conclusion The application of insulin degludec and in⁃sulin aspart can significantly improve the blood glucose level of patients with type 2 diabetes mellitus, the efficacy is more accurate, and the safety is higher, and it will not increase the occurrence of adverse reactions after the use of medication.[作者简介]戴卉（1985-），女，本科，主治医师，研究方向为内分泌科。